# One size does not fit all: rethinking IO–TKI use in favorable-risk metastatic ccRCC

**Authors:** Alejandro Valdés, Enrique Grande, Mauricio Burotto

PMC · DOI: 10.3389/fonc.2026.1783114 · Frontiers in Oncology · 2026-02-23

## Full-text entities

- **Genes:** PBRM1 (polybromo 1) [NCBI Gene 55193] {aka BAF180, PB1, RCC, SMARCH1}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}
- **Diseases:** endocrinopathies (MESH:C567425), toxicities (MESH:D064420), (e.g. pancreas or thyroid) metastases (MESH:D009362), hypertension (MESH:D006973), cytopenias (MESH:D006402), mOS (MESH:D011475), IMDC (MESH:D002292), tumor (MESH:D009369), hand-foot syndrome (MESH:D060831), disease (MESH:D004194), fatigue (MESH:D005221), diarrhoea (MESH:D003967)
- **Chemicals:** pazopanib (MESH:C516667), CheckMate (-), nivolumab (MESH:D000077594), ipilimumab (MESH:D000074324), sunitinib (MESH:D000077210)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12967987/full.md

## References

57 references — full list in the complete paper: https://tomesphere.com/paper/PMC12967987/full.md

---
Source: https://tomesphere.com/paper/PMC12967987